ABSTRACT
Cancer cells invoke phenotypic plasticity programs to drive disease progression and evade chemotherapeutic insults, yet until now there have been no validated clinical therapies targeting this process. Here, we identify a phenotypic plasticity signature associated with poor survival in basal/triple-negative breast cancer, in which androgen signalling is prominent. We establish that anti-androgen therapies block cancer stem cell function and prevent chemotherapy-induced emergence of new cancer stem cells. In particular, the anti-androgen agent seviteronel synergizes with chemotherapy to improve chemotherapeutic inhibition of primary and metastatic tumour growth and prevent the emergence of chemotherapy-resistant disease. We validate cytoplasmic AR expression as a clinical phenotypic plasticity biomarker that predicts poor survival and poor response to chemotherapy, and positive response to seviteronel plus chemotherapy. This new targeted combination therapy validates modulating phenotypic plasticity as an effective strategy to prevent and treat chemotherapy-resistant cancers with transformative clinical potential.
STATEMENT OF SIGNIFICANCE There are currently no curative therapies for patients with chemotherapy-resistant cancer. We demonstrate that modulating phenotypic plasticity prevents the emergence of chemotherapy-resistant disease in triple-negative breast cancer. This represents the first known validated clinical therapy leveraging phenotypic plasticity. Moreover, we identify a highly effective anti-androgen drug and a biomarker to select and treat patients best-suited to this new therapy. A clinical trial is underway (NCT04947189).
SUMMARY SENTENCE Blocking phenotypic plasticity is an effective targeted therapeutic strategy to treat cance
Competing Interest Statement
C.L.C is the founder and Managing Director of Kembi Therapeutics Pty Ltd that holds US patents for seviteronel. C.L.C and B.P.S.J are co-inventors on a patent for the method of use of seviteronel in combination with chemotherapy to treat cancer.
Funding Statement
This study was funded by a St. Vincents Hospital Research Grant, NHMRC Ideas grants APP1088122 and APP1181230, a National Breast Cancer Foundation research grant IIRS-19-092. L.R. is supported by a Ramon-Areces Fellowship. C.L.C and B.P.S.J were supported by the Nelune Foundation Rebecca Wilson Fellowship. C.L.C was supported by a CINSW Fellowship CDF181243. L.D.G. was supported by the Kinghorn Foundation. TEH was supported by a National Breast Cancer Foundation fellowship (IIRS-19-009). FVK and CAP are supported by an Australian Government Research Training Program (RTP) Scholarship.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Animal Experiments All experiments were approved by and conducted in accordance with the National Health and Medical Research Council Statement on Animal Experimentation, the requirements of New South Wales State Government legislation, and with the rules for animal experimentation of the Biological Testing Facility of the Garvan Institute and the Victor Chang Cardiac Research Institute (protocol #18/12). Treatment-naive TNBC clinical cohorts Tissue Microarrays representing 308 treatment-naive triple-negative breast cancer specimens collected from the Royal Prince Alfred Hospital, Concord Repatriation General Hospital and Royal North Shore Hospital in New South Wales, Australia. The studies were approved by the Royal Prince Alfred Hospital Human Ethics Review Committee (X14-0241) and by the Northern Sydney Local Health District Human Research Ethics Committee (X15-0388). SETUP trial clinical cohort Samples were stained and scored as above. The study was approved by the human research and ethics committees at all the participating institutions (Monash Medical Centre, Melbourne, Australia and Monash University, Melbourne, Australia) under protocol 03169A. Staining of PDXs and patient samples Ethical approval for AR and ZEB1 staining on human clinical cohorts and patient-derived xenograft samples was obtained and approved by the St Vincent's Hospital Human Research Ethics Committee (2019/ETH12832). Post-hoc biomarker analysis of Clarity-01 Phase II clinical trial Data used for this analysis are from the Clarity-01 clinical trial (IND133101, NCT02580448). The study was approved by the institutional review board at each participating site. Informed consent was obtained from all individual participants included in the study. Participating sites include: 1.Memorial Sloan Kettering Cancer Center 2.Gabrail Cancer Center 3.Duke University Hospital System 4.University of Colorado Cancer Center 5.Henry Ford Hospital 6.Massachusetts General Hospital 7.University of Texas Southwestern Medical Center 8.Virginia Oncology Associates 9.North Shore Hematology Oncology Associates, P.C. 10.The Ohio State University, Stefanie Spielman Comprehensive Breast Center 11.University of Louisville Hospital, James Graham Brown Cancer Center 12.Huntsman Cancer Institute 13.Hackensack University Medical Center 14.Oregon Health & Science University Community Hematology Oncology - Northwest 15.UNC Hospitals, The University of North Carolina at Chapel Hill 16.University of Alabama at Birmingham 17.University of Michigan 18.Mary Crowley Cancer Research Centers - Medical City 19.University of Minnesota Medical Center, Fairview 20.Charleston Hematology Oncology Associates, PA 21.Georgia Cancer Center at Augusta University 22.The Sarah Cannon Research Institute 23.Florida Cancer Specialists 24.Florida Cancer Specialists 25.US Oncology, Inc. / Texas Oncology - Baylor Charles A. Sammons Cancer Center 26.US Oncology, Inc. / Oncology Hematology Care, Inc. 27.US Oncology, Inc. / Nebraska Cancer Specialists 28.Precision Cancer Research / Brig Center for Cancer Care and Survivorship, LLC 29.US Oncology, Inc. / Rocky Mountain Cancer Centers 30.City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript or will be made available upon reasonable request to the authors.
